Citations

Clear

1053 citation(s) found for "Andre, F".

Real‐World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma ( RRMM ): An International Myeloma Working Group Immunotherapy Registry Real‐World Analysis
Janakiram, Murali , Tan, C. R., Mian, Hira, Huang, C Y, Popat, Rakesh , Martínez‐Lopez, Joaquín, Kastritis, Efsthathios, Chng, Wee-Joo, Kapoor, Prashant , Dave, Mrugakshi, Bal, Susan, Garderet, Laurent, Corraes, Andre De Menezes Silva , Riedhammer, Christine , Steinbrunn, Torsten, Nagarajan, Chandramouli, Einsele, Hermann, Martin, T, Krishnan, Amrita, Lin, Yi, Martínez‐López, Joaquín , Frigault, Matthew J. , Larrea, Carlos Fernández de , Mian, Hira , Tan, Carlyn R , Kastritis, Efstathios , Corona, Magdalene , Martinez-Lopez, Joaquin , Mian, Hira , Janakiram, Murali , Tan, Carlyn , Popat, Rakesh , Chng, Wee Joo , Bal, Susan , Garderet, Laurent , Steinbrunn, Torsten , Nagarajan, Chandramouli

Mayo Clinic

American Journal of Hematology | May 20, 2026 | Volume: 101 | Issue: 8 | Pages: 1928-1937

10.1002/ajh.70376 | PMID 42157444 Get It

ABSTRACT Talquetamab is a GPRC5D × CD3 bispecific antibody approved for relapsed/refractory multiple myeloma (RRMM). This is the first real‐world study to comprehensively report muco‐cutaneous toxicities, infections, and efficacy of talquetamab in 151 patients across five countries with the longest follow‐up reported enabling better efficacy and toxicity estimates. The median age was 64 years; high‐risk cytogenetics were present in 42%; ECOG ≥ 2 in 22%; 12% had creatinine clearance < 30; and 55% would not have met MonumenTAL‐1 eligibility. Patients received a median of 6 prior lines of therapy, 53% were penta‐refractory, and 75% received prior BCMA therapy. Talquetamab was associated with skin toxicity in 39.7%, nail toxicity in 75.5%, dysgeusia in 60.4%, and oral toxicities in 62.9%, with grade ≥ 3 events uncommon (≤ 4%) and dose interruptions infrequent (9.6% for skin toxicity, 6.9% for dysgeusia, and 4.0% for oral toxicities). These findings underscore the need for improved supportive care for muco‐cutaneous toxicities. In multivariate analysis, only platelet count < 50 (HR 1.8, 95% CI 1.15–2.83) was associated with inferior PFS, while penta‐refractory status, absolute lymphocyte count < 0.4, and prior BCMA‐targeted therapy were not statistically significant. With a median follow‐up of 12.7 months, the overall response rate was 67.6%, median progression‐free survival was 7 months, and 12‐month overall survival was 65%. This study shows that talquetamab efficacy is maintained in a heavily pretreated real‐world population with high prior BCMA exposure and notable comorbidity burden.
Resolving inflammatory bowel disease risk variants to genes and cell types
Zhang, Rui, Gettler, Kyle , Haritunians, Talin , Cleynen, Isabelle , Stevens, Christine R , Zhang, Qian , Tastad, Christopher, Medici, Catalina, Abreu, María T. , Achkar, Jean-Paul, Ahmad, Tariq, Bernstein, Charles, Brooks, Johanne , Bujanda, Luis, Butterworth, Jeffrey, Clark, Katie, Cummings, F, Buono, Joanne Del, Foley, Stephen, Franchimont, Denis , Hancock, L, Hart, Ailsa, Hooper, Patricia, Jarvis, Mark , Johnston, EL, Kemp, Cheryl, Kennedy, Nick, Lewis, James D. , Li, Andy, Louis, Édouard , Moayyedi, Paul, Moran, G , Newman, Bill, Oglesby, Arabis, Pekow, Joel, Perez, Kate J., Pollok, R, Radford-Smith, Graham , Raffals, L, Raine, Tim, Ramadas, Arvind, Ramakrishnan, S., Reinisch, Walter , Satsangi, Jack, Selinger, Christian, Shedwell, Sophy, Silverberg, Mark S. , Singh, Salil, Steel, Alan, Uhlig, Holm H. , Verma, Ajay, Weersma, Rinse K. , Xavier, Ramnik, Parkes, M, Lee, James C. , McGovern, D, Anderson, Carl A. , Lee, James , Raine, Tim , Zhang, Rui , Haritunians, Talin , Raine, Tim , Anderson, Carl A , Fachal, Laura , Cleynen, Isabelle , Stevens, Christine R. , Zhang, Qian , Tastad, Christopher , Do, Ron , Achkar, Jean–Paul , Ahmad, Tariq , Kok, Klaartje Bel , Butterworth, Jeffrey R., Cummings, Fraser , D’Amato, Mauro , Duerr, Richard H , Ellinghaus, David , Franchimont, Denis , Franke, André , Hart, Ailsa , Hooper, Patricia, Irving, Peter Miles , Julià, Antonio , Kennedy, Nicholas Alexander , Kupcinskas, Juozas , Latiano, Anna , Lewis, James D , McLaughlin, John , Moayyedi, Paul , Mowat, Craig , Newberry, Rodney D. , Perez, Kate J, Prescott, Natalie , Radford‐Smith, Graham L , Raffals, Laura E. , Reinisch, Walter , Rogler, Gerhard , Sands, Bruce E , Satsangi, Jack, Scharl, Michael , Schreiber, Stefan , Sebastian, Shaji , Selinger, Christian P. , Steed, Helen , Vermeire, Séverine , Halfvarson, Jonas , Daly, Mark J. , Lamb, Christopher A , Huang, Hailiang , McGovern, Dermot P.B. , Rioux, John D. , Cho, Judy H , Zhang, Rui

Mayo Clinic

No container title available | May 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.13.26352926 Get It

Abstract Inflammatory bowel diseases (IBD), principally Crohn’s disease (CD) and ulcerative colitis (UC), are common chronic disorders involving inflammation and often progressive tissue damage. Genome-wide association studies have mapped many risk signals, but the causal variants, effector genes and relevant cellular contexts remain difficult to resolve, limiting mechanistic interpretation and therapeutic translation. Here we performed a multi-ancestry GWAS meta-analysis of 125,992 individuals with IBD and more than 1.2 million controls, identifying 619 independent association signals (374 novel) at 420 IBD regions that account for 77–80% of SNP-based heritability. Fine-mapping resolved 81 high-confidence variants, 41 not previously reported. Although most signals were shared between CD and UC, 39% showed IBD subtype specificity, with UC signals showing stronger enrichment in functional annotations from intestinal epithelial, secretory and enteroendocrine cells, and CD showing stronger genetic correlations with circulating inflammatory biomarkers, including C-reactive protein and glycoprotein acetylation. Latent causal modelling supported a causal effect of decreased high-density lipoprotein on CD risk. By integrating bulk and single-cell eQTL and pQTL resources using colocalisation and Mendelian randomisation, together with coding-variant evidence from exome sequencing, we prioritised 664 candidate effector genes across 341 signals, including 390 newly implicated IBD genes, revealing new biological mechanisms and candidate therapeutic targets supported by human genetics.
Benchmarking Surgical Outcomes for Endoscopic Transnasal Craniopharyngioma Resection: Implications for Clinical Practice From the RAPID Consortium
Tenhoeve, Samuel A. , Orton, Cody, Gautam, Diwas, Silverstein, Julie M., Kim, Albert H., Evans, James J., Barkhoudarian, Garni, Fernandez-Miranda, Juan C., Pacione, Donato , Kim, Won, Bergsneider, Marvin, Zada, Gabriel, Kshettry, Varun R., Wu, Kyle C., Prevedello, Daniel M., Benjamin, Carolina G., Gompel, Jamie Van, Catalino, Michael P., Mamelak, Adam N., Zwagerman, Nathan T., Cheok, Stephanie K., Little, Andrew S., Mendoza, Michelle Magana, Zenonos, Georgios A., Gardner, Paul A., Karsy, Michael, Morshed, Ramin A., Blackburn, Spiros L., Mukherjee, Debraj, Beer-Furlan, Andre, Couldwell, William T., Karsy, Michael , Van Gompel, Jamie, Palit, Sandhya R. , Rennert, Robert C , Karsy, Michael , Orton, Cody , Gautam, Diwas , Silverstein, Julie , Kim, Albert H , Evans, James J., Barkhoudarian, Garni , Fernandez‐Miranda, Juan C. , Bergsneider, Marvin , Chicoine, Michael , Zada, Gabriel , Kshettry, Varun R. , Prevedello, Daniel M. , Gompel, Jamie J. Van , Catalino, Michael Paul, Mamelak, Adam N, Zwagerman, Nathan T. , Cheok, Stephanie , Little, Andrew S. , Zenonos, Georgios A. , Gardner, Paul A. , Morshed, Ramin A. , Blackburn, Spiros L., Mukherjee, Debraj , Beer‐Furlan, André , Couldwell, William T.

Mayo Clinic

Operative Neurosurgery | May 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1227/ons.0000000000002055 | PMID 42138611 Get It

BACKGROUND AND OBJECTIVES: Craniopharyngiomas are complex intracranial tumors that pose significant challenges in surgical management. We aimed to develop risk-stratified surgical outcome benchmarks for adult patients undergoing endoscopic craniopharyngioma resection by using the Registry of Adenomas of the Pituitary and Related Disorders database to facilitate comparisons across institutions and guide clinical decision-making. METHODS: A retrospective cohort of adult patients (18 years and older) with craniopharyngioma undergoing a first-time endoscopic transnasal surgery across 14 academic centers in the United States was analyzed using data collected from 2011 to 2024. Patients were stratified into low-risk and high-risk cohorts based on criteria including age, body mass index, selected tumor characteristics (size, infundibular relationship, intraventricular extension), and previous radiation. Surgical outcomes were analyzed, and benchmarking ranges were defined using the established methodology. RESULTS: The overall cohort included 318 patients with a mean age of 50 years. Upon benchmarking analysis (50th-75th percentile performance), low-risk patients (n = 136) had a median length of stay of 4.0 to 6.0 days, 90-day readmission rates of 15.5% to 22.2%, skilled nursing facility discharge rates of <1.0%, postoperative cerebrospinal fluid leak incidence of <1.0% to 14.3%, gross total resection rates of 50.0% to 60.8%, new postoperative arginine vasopressin deficiency rates of 33.3% to 50.0%, and tumor progression/recurrence rates of <1.0% to 18.3% over a median follow-up period of 27.0 (IQR 10.5-56.5) months. Benchmarking ranges were proposed for each outcome to facilitate cross-institutional comparisons. CONCLUSION: Establishing surgical outcome benchmarks for adult patients undergoing craniopharyngioma resection using data from the Registry of Adenomas of the Pituitary and Related Disorders provides a framework for assessing surgical performance and guiding clinical decision-making. Benchmark ranges can inform institutional quality improvement efforts, perioperative risk stratification, and patient counseling regarding expected postoperative outcomes.
Exome sequencing directly implicates 68 genes in inflammatory bowel disease
Zhu, Ruifei , Zhang, Qian , Yuan, Kai , Zhang, Rui , Turvey, Alexandra K. , Stevens, Christine R , Ahmad, Tariq, Bernstein, Çharles N. , Bokemeyer, Bernd , Brooks, Johanne , Butterworth, Jeffrey, Clark, Katie, Cummings, F, Ennis, Sarah, Färkkilä, M, Faubion, William A. , Foley, Stephen, Franchimont, Denis , Hancock, L, Hart, Ailsa, Hooper, Patricia, Irving, Peter, Jarvis, Mark , Johnston, EL, Karlson, Elizabeth W, Kemp, Cheryl, Kennedy, Nick, Lees, Charlie, Lewis, James D. , Li, Andy, Louis, Édouard , McGovern, Dermot P.B., Oglesby, Arabis, Perez, Kate J, Pollok, R, Raine, Tim, Ramadas, Arvind, Ramakrishnan, S., Sands, Bruce, Satsangi, Jack, Schreiber, Stefan, Selinger, Christian, Shedwell, Sophy, Silverberg, M, Singh, Salil, Steel, Alan, Uhlig, H, Verma, Ajay, Vermeire, Séverine , Weersma, Rinse K. , Xavier, Ramnik, Parkes, Miles, Rioux, John D. , Anderson, Carl A. , Raine, Tim , Uhlig, Holm H. , Fachal, Laura , Bernstein, Charles Noah , Bokemeyer, Bernd , Brant, Steven R , Cho, Judy H , Duerr, Richard H , Faubion, William , Franchimont, Denis , Franke, André , Kupcinskas, Juozas , Lamb, Christopher A , Lewis, James D , Loescher, Britt-Sabina , Louis, Edouard , McCauley, Jacob L , Moayyedi, Paul , Newberry, Rodney D , Palotie, Aarno V. , Pekow, Joel , Prescott, Natalie , Sabic, Ksenija , Sands, Bruce E , Silverberg, Mark S , Sokol, Harry , Vermeire, Séverine , Weersma, Rinse K , Xavier, Ramnik J , Yu, Mingrui , Rioux, John D , Daly, Mark J. , Huang, Hailiang , Anderson, Carl A , Raine, Tim , Zhang, Qian , Yuan, Kai , Stevens, Christine R. , Fachal, Laura , Ahmad, Tariq , Kok, Klaartje Bel , Butterworth, Jeffrey R., Cummings, Fraser , Ennis, Sarah A. , Färkkilâ, Martti , Hart, Ailsa , Hooper, Patricia, Irving, Peter Miles , Karlson, Elizabeth W. , Kennedy, Nicholas Alexander , Lees, Charlie W. , McCauley, Jacob L. , McGovern, Dermot P.B. , McLaughlin, John , Moayyedi, Paul , Moran, G , Newberry, Rodney D. , Pekow, Joel , Satsangi, Jack, Sazonovs, Aleksejs , Schreiber, Stefan , Selinger, Christian P. , Steed, Helen , Parkes, Miles , Zhang, Rui

Mayo Clinic

No container title available | May 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.08.26352648 | PMID 42180385 Get It

Abstract Inflammatory bowel disease (IBD) is a chronic immune-mediated disorder of the gastrointestinal tract whose genetic basis is only partly resolved because most risk variants identified by genome-wide association studies (GWAS) lie in non-coding regions, limiting direct gene assignment and biological interpretation 1,2 . Here we analysed whole-exome and whole-genome sequencing data from 86,213 IBD cases and 478,363 controls of European ancestry. We identified 68 IBD genes directly implicated by conditionally independent protein-coding associations across the allele frequency spectrum. Many newly implicated IBD genes are supported by orthogonal genomic or pleiotropic evidence, pointing to disease-related pathways and nominating targets with therapeutic relevance. We further identified allelic series and non-additive effects at key loci such as NOD2 and TYK2. These results show that large-scale sequencing can resolve disease genes and pathways that remain ambiguous from non-coding association alone, providing a more direct route from human genetics to biological insight and therapeutic hypotheses.
Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy
Investigators, The HCMR, Kolm, Paul, DiMarco, John P., Desai, M Y, Ho, Carolyn Y., Kwong, Raymond Y., Dolman, Sarahfaye , Nickens, Patrice Desvigne, GELLER, NANCY, Kim, Dong-Yun, Schulz-Menger, Jeanette, Friedrich, M G, Maron, Martin S., Appelbaum, Evan, Francis, Gary S., Greenberg, Barry, Jerosch-Herold, Michael, Piechnik, Stefan, Mahmod, Masliza, Jacoby, Daniel L., Baldassare, Lauren A., White, J, Helms, Adam S., Choudhury, Lubna , Michels, Michelle, Salerno, Michael , Heitner, Steven B., Masri, Ahmad, Prasad, Sanjay , Plein, S V E N, Madias, Christopher, Mahrholdt, Heiko , Bucciarelli-Ducci, C, Nightingale, Angus K. , Weinsaft, Jonathan W., McCann, Gerry P., Rossum, Albert van, Germans, Tjeerd , Williamson, Eric E. , Geske, Jeffrey B., Dawson, D, Mongeon, François‐Pierre , Olivotto, Iacopo, Crean, Andrew , Woo, Anna, Owens, Anjali T., Anderson, L , Biagini, Elena, Newby, David E., Andre, Florian, Berry, C, Kim, Bette, Larose, Eric, Abraham, Theodore P., Sherrid, Mark V., Gelfand, Eli V. , Nagueh, Sherif F. , Rimoldi, Ornella, Camici, Paolo, Elstein, Eleanor , Watkins, Hugh, Weintraub, William S., Neubauer, Stefan, Schulz‐Menger, Jeanette , Nightingale, Angus K , Dawson, Dana , Kramer, Christopher M. , Kolm, Paul , Desai, Milind Y. , Ho, Carolyn Y. , Kwong, Raymond Y.K. , Desvigne‐Nickens, Patrice , Kim, Dong-Yun, Friedrich, Matthias G. , Maron, Martin S. , Appelbaum, Evan A., Link, Mark S. , Greenberg, Barry, Jerosch‐Herold, Michael , Piechnik, Stefan Kazimierz , Mahmod, Masliza , Raman, Betty , Jacoby, Daniel Louis , Baldassarre, Lauren A. , White, James A. , Chiribiri, Amedeo , Helms, Adam S. , Michels, Michelle , Bradlow, William M. , Heitner, S B, Masri, Ahmad , Mohiddin, Saidi , Plein, Sven , Madias, Christopher A. , Bucciarelli‐Ducci, Chiara , Weinsaft, Jonathan W. , Kim, Han W. , McCann, Gerry P , Rossum, Albert C. van , Geske, Jeffrey B. , Flett, Andrew S. , Olivotto, Iacopo , Woo, Anna, Owens, Anjali , Sharma, Sanjay , Biagini, Elena , Newby, David E. , André, Florian , Berry, Colin , Larose, Éric , Abraham, Theodore P. , Hays, Allison G , Sherrid, Mark V. , Rimoldi, Ornella , Camici, Paolo G. , Autore, Camillo , Watkins, Hugh , Weintraub, William S. , Neubauer, Stefan

Mayo Clinic

JAMA | May 11, 2026 | Volume: 335 | Issue: 22 | Pages: 1959

10.1001/jama.2026.5633 | PMID 42113540 Get It

Importance Current risk prediction guidelines for hypertrophic cardiomyopathy predict only sudden cardiac death and are imperfect, leading to avoidable deaths and unnecessary implantable cardioverter defibrillators. Objective To combine prospectively collected clinical history, imaging, genetic, and biomarker data to improve risk prediction of adverse events in hypertrophic cardiomyopathy. Design, Setting, and Participants A total of 2750 patients with hypertrophic cardiomyopathy were prospectively enrolled in the registry-based study from 44 sites in North America and Europe with expertise in hypertrophic cardiomyopathy and cardiac magnetic resonance (CMR) imaging. Participants were enrolled from April 1, 2014, to April 7, 2017. Exposures Patients underwent a health history questionnaire, blood sampling for biomarkers and genotyping, and contrast-enhanced CMR. Patients were followed up yearly by telephone and through records review regarding event documentation. Main Outcomes and Measures The predefined composite adjudicated primary end point was time to first event for hypertrophic cardiomyopathy–related deaths; nonfatal sustained ventricular arrhythmias (VAs) requiring cardioversion or defibrillation; and left ventricular (LV) assist device implant or heart transplant. A secondary end point was a composite of sudden cardiac death and nonfatal VA events. The elastic-net method identified the most important predictors. Cox proportional hazards regression assessed associations with time to the first end point. Results Of the 2750 prospectively enrolled patients, 2698 (98%) had analyzable data after 9 were excluded because they had hypertrophic cardiomyopathy phenocopies and 43 withdrew. Of these remaining patients, 1919 (71%) were male, mean age was 50 years (SD, 11 years), and 423 (16%) were from underrepresented racial and minority groups. The mean follow-up was 6.9 years (SD, 2.1 years). The primary event model in 104 patients included LV scar as a percentage of LV mass by late gadolinium enhancement (LGE%; hazard ratio [HR], 1.86; 95% CI, 1.58-2.20; P &amp;lt; .001), LV mass index (HR, 1.09; 95% CI, 1.01-1.17; P = .03), LV end-systolic volume index (HR, 1.28; 95% CI, 1.12-1.46; P &amp;lt; .001 ), all per 10-unit increase, history of heart failure at study entry (HR, 2.89; 95% CI, 1.75-4.77; P &amp;lt; .001), and log N-terminal pro–B-type natriuretic peptide (NT-proBNP; HR, 1.41; 95% CI, 1.17-1.70; P &amp;lt; .001) level per log unit, (C index for all, 0.77). An LGE percentage of the LV mass of 9% or higher substantially increased the primary composite event rate ( P = .001). The secondary sudden cardiac death and VA risk factor model (in 69 patients) included LGE%, LV mass index, LV ejection fraction, and log(NT-proBNP) (C index, 0.76). Conclusions and Relevance These results provide prospective evidence for incorporating cardiac magnetic resonance and NT-proBNP in the evaluation of patients with hypertrophic cardiomyopathy. Trial Registration ClinicalTrials.gov Identifier: NCT01915615
Acupressure for anxiety: a pilot study of a nurse-led acupressure intervention for patients receiving chemotherapy
Rhee, Laura, Cutshall, Susanne, Metzger, Abbey, Kruger, Margaret, Burckhard, Jenna, Mallory, Molly J., Whalen, Fran, D'Andre, Stacy, Ruddy, Kathryn, Loprinzi, Charles L. , Manggaard, Jenn M., Rake, Elizabeth Cathcart-, Cathcart-Rake, Elizabeth , Mallory, Molly , Ruddy, Kathryn J , Cathcart-Rake, Elizabeth J , Rhee, Laura, Cutshall, Susanne M. , Metzger, Abbey K., Kruger, Margaret B., Burckhard, Jenna, D’Andre, Stacy D. , Ruddy, Kathryn J. , Fischer, Karen M.

Mayo Clinic

The Oncologist | April 28, 2026 | Volume: 31 | Issue: 8 | Pages: No page available

10.1093/oncolo/oyag166 | PMID 42063228 Get It

Abstract Background Anxiety is a common symptom experienced by patients with cancer, who are increasingly interested in non-pharmacologic symptom management. Acupressure, a noninvasive intervention thought to impact the neurohormonal axis, has shown promise in reducing anxiety. However, research on acupressure for anxiety in patients with cancer has been limited. Methods Individuals receiving chemotherapy, who reported baseline anxiety, were eligible for this study. Consenting participants received one 15-minute nurse-led acupressure session and completed pre- and post-intervention surveys. The primary endpoint was a change in anxiety. Participants were also asked about symptoms of nausea, pain, well-being, relaxation, worry, and distress. Participants were invited to learn self-acupressure techniques. These participants were asked to complete a final survey 1-week post-intervention. Results Thirty adult patients participated in this study. Mean baseline anxiety was 5 on a 0 to 10 Likert scale. Immediate post-intervention anxiety scores significantly improved for all thirty patients to an average of 2.0 (P &lt; .001). Mean nausea scores improved from 1.5 at baseline to 0 post-intervention (P &lt; .001), and pain scores improved from 2.0 at baseline to 1.0 post-intervention (P = .001). Participants reported significant improvement in sense of wellbeing (P = .0004), distress (P &lt; .001), ability to achieve relaxation (P &lt; .001), and ability to control their worries (P &lt; .001). The improvement in anxiety, well-being, and relaxation was sustained at one week. 100% of participants stated that they would recommend acupressure for symptom management. Conclusion Acupressure is a promising non-pharmacologic intervention for the management of cancer-associated anxiety.
Global Longitudinal Assessment of MASLD Using Magnetic Resonance Elastography ( GOLDMINE ): A Multi‐Center, International Prospective Cohort Study of Imag
Sharpton, Suzanne R. , Diaz, Luis Antonio, Pepin, Kay , Amangurbanova, Maral , Madamba, Egbert , Bettencourt, Ricki , Singh, Seema, Dalupang, Mary, Tesfai, Kaleb , Middleton, Michael S. , Behling, C, Nakajima, Atsushi , Imajo, Kento , Ogawa, Yuji, Halegoua‐DeMarzio, Dina, Huang, Daniel Q., Balakrishnan, Maya, Gray, Meagan , Rodriguez, Manuel, DeLeon, Andre, Puskoor, Rohit, Behari, Jaideep , Hansen, Lars, Miller, Cynthia, Medici, Valentina , Boursier, Jerome, Richards, Lisa, Díaz, Luis Antonio , Sharpton, Suzanne , Díaz, Luis A , Nakajima, Atsushi , Imajo, Kento , Huang, Daniel Q , Vuppalanchi, Raj , Medici, Valentina , Tincopa, Monica , Ehman, Richard , Singh, Seema, Valasek, Mark A. , Dunn, Winston , Caussy, Cyrielle , Mohanty, Arpan , Huang, Daniel Q. , Fuchs, Michael A. , Hameed, Bilal , Stine, Jonathan G. , Balakrishnan, Maya , Vuppalanchi, Raj , Sarkar, Souvik , Boursier, Jerome, Tincopa, Monica A. , Ajmera, Veeral , Sirlin, Claude B. , Ehman, Richard L. , Loomba, Rohit

Mayo Clinic

Alimentary Pharmacology & Therapeutics | April 22, 2026 | Volume: 64 | Issue: 3 | Pages: 334-344

10.1111/apt.70696 | PMID 42017265 Get It

ABSTRACT Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) exhibits marked heterogeneity in fibrosis progression and liver‐related outcomes. Liver biopsy is not feasible for longitudinal risk stratification at scale, creating a need for validated non‐invasive biomarkers, particularly imaging biomarkers, that can predict clinically meaningful disease progression and liver‐related outcomes. Aims To describe the design and rationale of the GOLDMINE study, established to determine whether non‐invasive imaging biomarkers predict MASLD progression and liver‐related clinical outcomes. Methods GOLDMINE is an investigator‐initiated, multi‐centre, international longitudinal cohort enrolling up to 1000 adults with either biopsy‐proven MASLD or MASLD cirrhosis across the full fibrosis spectrum. Participants are recruited from 15 sites in the US and 4 international sites (Japan, Singapore and France). At baseline, participants undergo clinical phenotyping, vibration‐controlled transient elastography, and advanced magnetic resonance imaging (MRI), including proton‐density‐fat‐fraction and magnetic resonance elastography (MRE). MRI (and biospecimen banking) is repeated at 2‐year intervals (years 2 and 4), with annual follow‐up visits for up to 10 years. Baseline liver histology is centrally processed, digitized and reviewed by a single expert hepatopathologist; all MRI/MREs are centrally interpreted. Results The prespecified clinical outcomes include progression to cirrhosis, clinically significant portal hypertension, major adverse liver‐related outcomes (ascites, hepatic encephalopathy, portal hypertensive bleeding, liver transplantation/qualification), hepatocellular carcinoma, major adverse cardiovascular events, and all‐cause mortality, with independent central adjudication of all events. Conclusions GOLDMINE establishes a rigorously phenotyped MASLD cohort integrating centralized histology, advanced MRI‐based biomarkers, longitudinal biobanking, and adjudicated outcomes, providing a platform to validate imaging and blood‐based prognostic biomarkers in MASLD.
Lymphocyte dynamics after CAR ‐T therapy for non‐Hodgkin lymphoma
Dingli, Sarah , Rothweiler, Paul , Corraes, Andre De Menezes Silva, Atallah‐Yunes, Suheil Albert , Ansell, Stephen M. , Bennani, N Nora, Johnston, Patrick B., Khurana, Arushi , Paludo, Jonas, Bisneto, J. C. Villasboas, Wang, Y, Lin, Yi, Erdman, Arthur G. , Atallah-Yunes, Albert , Durani, Urshila , Wang, Yucai , Erdman, Arthur G , Dingli, David , Corraes, Andre De Menezes Silva , Bennani, N. Nora , Durani, Urshila , Johnston, Patrick B. , Paludo, Jonas , Bisneto, J.C.C. Villasboas, Lin, Yi, Dingli, David

Mayo Clinic

British Journal of Haematology | April 21, 2026 | Volume: 209 | Issue: 1 | Pages: 189-196

10.1111/bjh.70502 | PMID 42011548 Get It

Summary Chimeric antigen receptor T cells directed against CD‐19 are highly effective therapies for various subtypes of B‐cell non‐Hodgkin lymphoma (NHL). We have studied the impact of patient‐specific lymphocyte growth kinetics after lymphoid depletion chemotherapy on both long‐term outcomes and toxicity in patients with diffuse large B‐cell non‐Hodgkin lymphoma (DLBCL). The growth of the lymphocyte populations early after chimeric antigen receptor T‐cell (CAR‐T) therapy is well described by an exponential function and the growth rate of the cells appears to be one of the most critical determinants of overall survival in these patients. The maximum lymphocyte peak and the area under curve for lymphocytes within the first 4 weeks after CAR‐T therapy had no impact on survival. Receiver operator characteristic analysis determined that a replication rate ≥0.3876/day is associated with superior rates of complete response and durable responses. This threshold is associated with higher grades of cytokine release syndrome and the need for tocilizumab. However, patients with this threshold have a median overall survival of 3.04 years compared to 1.035 years for patients with slower lymphocyte replication ( p = 0.0206). The major determinant of depth of response and durability of response to CAR‐T in NHL is the speed of lymphocyte expansion.